osimertinib
astrazeneca
['osimertinib', 'nsclc', 'sclc']
 #asco2023 presents striking data of osimertinib in resected egfr-mutated nsclc. 5 yr os 88% vs placebo 78%; well tolerated; cns penetration reduces mets to cns; and hits a key resistance pathway. bravo. 
Devoted to #endcancer suffering. Scientist, Physician, Educator, Entrepreneur, Advocate. Professor & Past President @MDAndersonNews.  Views expressed are my own